outcome in advanced ovarian cancer following an appropriate and comprehensive effort at upfront cytoreduction: a twenty-year experience in a single cancer institute
Clicks: 72
ID: 220945
2010
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
21.3
/100
72 views
6 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #86 of 87 articles by views in Langmuir : the ACS journal of surfaces and colloids
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Objectives. The purpose of this retrospective evaluation of advanced-stage ovarian cancer patients was to compare outcome with published findings from other centers and to discuss future options for the management of advanced ovarian carcinoma patients. Methods. A retrospective series of 340 patients with a mean age of 58 years (range: 17–88) treated for FIGO stage III and IV ovarian cancer between January 1985 and January 2005 was reviewed. All patients had primary cytoreductive surgery, without extensive bowel, peritoneal, or systematic lymph node resection, thereby allowing initiation of chemotherapy without delay. Chemotherapy consisted of cisplatin-based chemotherapy in combination with alkylating agents before 2000, whereas carboplatin and paclitaxel regimes were generally used after 1999-2000. Overall survival and disease-free survival were analyzed by the Kaplan-Meier method and the log-rank test. Results. With a mean followup of 101 months (range: 5 to 203), 280 events (recurrence or death) were observed and 245 patients (72%) had died. The mortality and morbidity related to surgery were low. The main prognostic factor for overall survival was postoperative residual disease (P<.0002), while the main prognostic factor for disease-free survival was histological tumor type (P<.0007). Multivariate analysis identified three significant risk factors: optimal surgery (RR=2.2 for suboptimal surgery), menopausal status (RR=1.47 for postmenopausal women), and presence of a taxane in the chemotherapy combination (RR=0.72). Conclusion. These results confirm that optimal surgery defined by an appropriate and comprehensive effort at upfront cytoreduction limits morbidity related to the surgical procedure and allows initiation of chemotherapy without any negative impact on survival. The impact of neoadjuvant chemotherapy to improve resectability while lowering the morbidity of the surgical procedure is discussed.
| Reference Key |
marszalek2010internationaloutcome
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Anne Marszalek;Séverine Alran;Suzy Scholl;Virginie Fourchotte;Corinne Plancher;Christophe Rosty;Jean Philippe Meyniel;Vincent De Margerie;Thierry Dorval;Anne De La Rochefordière;Paul Cottu;Peter Petrow;Xavier Sastre-Garrau;Rémy Jacques Salmon |
| Journal | Langmuir : the ACS journal of surfaces and colloids |
| Year | 2010 |
| DOI |
10.1155/2010/214919
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.